Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
Rupert Bartsch(Universitätszahnklinik Wien), G. Steger(Aristotle University of Thessaloniki), Florian Fitzal, Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Anna S. Berghoff(Medical University of Vienna), Catharina DeVries(Comprehensive Cancer Center Vienna), Andrea Rottenfusser(Comprehensive Cancer Center Vienna), Margaretha Rudas(Comprehensive Cancer Center Vienna), Peter Dubsky(Hirslanden Klinik St. Anna), Christoph Zielinski(Vienna General Hospital), Ursula Pluschnig(Medical University of Vienna), Robert M. Mader(Centre de Recherche en Économie et Management), Karin Dieckmann(University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 77
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830